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A 69-year-old woman was diagnosed right breast cancer which was a stage III invasive 1 
ductal breast carcinoma with high proliferative activity (Ki-67 expression: 30% 2 
positively-stained cell), positive hormone receptor (androgen receptor) and HER2 3 
overexpressed. Echocardiography before initial chemotherapy showed normal left 4 
ventricular (LV) size and function. After the initial echocardiographic study, the patient 5 
was given 4 cycles of epirubicin and cyclophosphamide, followed by 3 cycles of 6 
trasuzumab and paclitaxel as neoadjuvant chemotherapy. The patient was performed 7 
surgical resection of right breast cancer at 6 months later from initial chemotherapy. 8 
After initial chemotherapy, global longitudinal strain (GLS) seemed to decrease from 9 
the baseline values, however LV ejection fraction (EF) did not change within normal 10 
limit during 15 months follow-up. After 15 months from initial chemotherapy, although 11 
serum B-type natriuretic peptide is 30pg/ml and high sensitive troponin I is <5mg/dl, 12 
she had mild exertional breathlessness. Transthoracic echocardiography after 15 months 13 
from initial chemotherapy showed decreased LVEF of 33% (FIGURE), then she was 14 
diagnosed chemotherapy-related cardiac dysfunction (CTCRD). We stopped 15 
chemotherapy, and patient was provided heart failure pharmacological treatment with 16 
enalapril 2.5mg, carvedilol 2.5mg, and azosemide 15mg/day (SUPPLEMENT 1). With 17 
a slow pharmacological up-titration, LVEF and GLS had normalized. 18 
This case shows two important insights. The first is that importance of regular 19 
sequential follow-up examination. We can find the tiny change of LV systolic 20 
dysfunction by performing regular follow-up examinations. CTRCD is occurred in 6-21 
9% of patients with chemotherapy within 12 months from the last administration [1]. 22 
However, many literatures reported that CTRCD also occurred in remote phase [2]. We 23 




































































imaging or multigated acquisition scan because CTRCD is defined by the value of 1 
LVEF. The second is to confirm that we can detect the early change of LV systolic 2 
dysfunction due to chemotherapy by GLS rather than LVEF. Previous literature reported 3 
that the patients with 11% decreased of ΔGLS after chemotherapy had more 4 
development of CTRCD [3]. SUPPLEMENT 1 shows the measurements of LVEF and 5 
GLS every 3 months during follow-up. The decrease of ΔGLS of 14% at follow-up 6 
study 3 months later from initial chemotherapy may indicate the early impairment of LV 7 
myocardium. According to our case, it is important to evaluate regularly cardiac systolic 8 
function after chemotherapy, and GLS is more useful than conventional values such as 9 
LVEF to detect early stage of myocardial impairment as pre-stage of CTRCD.  10 
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FIGURE LEGENDS 1 
FIGURE. 2 
This is the time course figure about global longitudinal strain (GLS) and left ventricular 3 
ejection function (LVEF): Upper figures show the polar maps by using speckle tracking 4 
method and lower figure shows time courses of ΔGLS and ΔLVEF. The decrease of 5 
ΔGLS of 14% at follow-up study 3 months later from initial chemotherapy was shown 6 
(arrow). 7 
 8 
SUPPLEMENT 1. 9 
This is the flow diagram of chemotherapy and cardiac protection therapy.  10 
 11 
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basaline development of CTCRD
Figure
